A5090605318- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Immunotherapy and Immune Responses
- Sarcoma Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Complementary and Alternative Medicine Studies
- T-cell and Retrovirus Studies
- T-cell and B-cell Immunology
- Hematopoietic Stem Cell Transplantation
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Single-cell and spatial transcriptomics
- Genetic factors in colorectal cancer
- Acute Lymphoblastic Leukemia research
- Virus-based gene therapy research
Innlandet Hospital Trust
2022-2025
Inland Hospital
2022-2025
University Hospital of North Norway
1999-2025
Oslo University Hospital
2015-2024
University of Oslo
2014-2023
Norwegian Cancer Society
2007-2016
Cancer Clinic
2016
Aarhus University Hospital
2009-2013
Med-Storm Innovation (Norway)
2007-2013
Jönköping University
2009
Advanced-stage follicular B-cell lymphoma is considered incurable. Anti-CD20 radioimmunotherapy effective in patients who have had a relapse after chemotherapy or refractory lymphoma, but it has not been tested previously untreated patients.Seventy-six with stage III IV received as initial therapy single course of treatment 131I-tositumomab (registered Tositumomab and Iodine I 131 [the Bexxar therapeutic regimen]). This consisted dosimetric dose tositumomab 131I-labeled followed one week...
We conducted an international, randomized, phase III trial to evaluate the efficacy and safety of consolidation with yttrium-90 ((90)Y)-ibritumomab tiuxetan in patients advanced-stage follicular lymphoma first remission.Patients CD20(+) stage or IV lymphoma, who achieved a complete response (CR)/unconfirmed CR (CRu) partial (PR) after first-line induction treatment, were randomly assigned receive (90)Y-ibritumomab (rituximab 250 mg/m(2) on day -7 0 followed by 14.8 MBq/kg; maximum 1,184 MBq)...
Mantle cell lymphoma (MCL) is a heterogenic non-Hodgkin entity, with median survival of about 5 years. In 2008 we reported the early - based on observation time 4 years results Nordic Lymphoma Group MCL2 study frontline intensive induction immunochemotherapy and autologous stem transplantation (ASCT), more than 60% event-free at years, no subsequent relapses reported. Here present an update after 6·5 The overall are still excellent, response duration longer 10 7·4 However, six patients have...
In recent decades, the prognosis of Mantle Cell Lymphoma (MCL) has been significantly improved by intensified first-line regimens containing cytarabine, rituximab and consolidation with high-dose-therapy autologous stem cell transplantation. One such strategy is Nordic MCL2 regimen, developed Group. We here present 15-year updated results study after a median follow-up 11·4 years: For all patients on an intent-to-treat basis, overall progression-free survival was 12·7 8·5 years,...
Tisagenlecleucel is approved for adults with relapsed/refractory (r/r) follicular lymphoma (FL) in the third- or later-line setting. The primary analysis (median follow-up, 17 months) of phase 2 ELARA trial reported high response rates and excellent safety profile patients extensively pretreated r/r FL. Here, we report longer-term efficacy, safety, pharmacokinetic, exploratory biomarker analyses after median follow-up 29 months (interquartile range, 22.2-37.7). As March 2022, 97 FL (grades...
Summary Mantle cell lymphoma ( MCL ) is an aggressive B lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem transplantation, such as the Nordic 2/3 protocols. In 2008, a international prognostic index MIPI was created to enable stratification clinical diverse patients into three risk groups. So far, in routine limited, it shown that inadequately separates low intermediate group patients. To improve outcome...
In recent years, the outcome of mantle cell lymphoma (MCL) has improved, especially in younger patients, receiving cytarabine-containing chemoimmunotherapy and autologous stem transplantation. Nevertheless, a proportion MCL patients still experience early failure. To identify biomarkers anticipating failure intensive chemotherapy MCL, we performed target resequencing DNA profiling purified tumor samples collected from enrolled prospective FIL-MCL0208 phase 3 trial (high-dose followed by...
Checkpoint blockade can reverse T-cell exhaustion and promote antitumor responses. Although blocking the PD-1 pathway has been successful in Hodgkin lymphoma, response rates have modest B-cell non-Hodgkin lymphoma (NHL). Coblockade of checkpoint receptors may therefore be necessary to optimize Here, characterization coinhibitory receptor expression intratumoral T cells from different NHL types identified TIGIT as frequently expressed receptors. Tumors patients were enriched CD8+ CD4+...
Purpose: T cells infiltrating follicular lymphoma (FL) tumors are considered dysfunctional, yet the optimal target for immune checkpoint blockade is unknown. Characterizing coinhibitory receptor expression patterns and signaling responses in FL T-cell subsets might reveal new therapeutic targets.Experimental Design: Surface of 9 receptors governing function was characterized from lymph node healthy donor tonsils peripheral blood samples, using high-dimensional flow cytometry. The results...
. To describe the development of Patient Experiences Questionnaire (PEQ) and to evaluate reliability validity constructed summed rating scales.Literature review, focus groups pilot surveys. Two national cross-sectional studies performed in 1996 1998.Two postal surveys a sample 14 hospitals stratified by geographical region hospital size. Subjects. Patients consecutively discharged from surgical wards internal medicine. The included 36 845 patients 19 578 responded (53%).We 10 scales based on...
Minimal residual disease (MRD) is predictive of clinical progression in mantle-cell lymphoma (MCL). According to the Nordic MCL-2 protocol we prospectively analyzed efficacy pre-emptive treatment using rituximab MCL patients molecular relapse after autologous stem cell transplantation (ASCT).MCL enrolled onto study, who had polymerase chain reaction (PCR) detectable markers and underwent ASCT, were followed with serial PCR assessments MRD consecutive bone marrow peripheral blood samples...
T cells modified to express chimeric antigen receptor (CAR) targeting CD19 (CD19CAR) have produced remarkable clinical responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. CD19CAR T-cell therapy has also demonstrated prominent effects non-Hodgkin lymphoma (B-NHL) patients. However, a subset of who relapse after outgrowth CD19- tumor cells. Hence, development alternative CARs other markers represents an unmet medical need for leukemia and B-NHL. Here, we...